Ana Espinel-Ingroff 1, Elizabeth Johnson 2, Hans Hockey 3 and Peter Troke 4 *
|
|
- Georgiana Day
- 6 years ago
- Views:
Transcription
1 Journal of Antimicrobial Chemotherapy (2008) 61, doi: /jac/dkm518 Advance Access publication 25 January 2008 Activities of voriconazole, itraconazole and amphotericin B in vitro against 590 moulds from 323 patients in the voriconazole Phase III clinical studies Ana Espinel-Ingroff 1, Elizabeth Johnson 2, Hans Hockey 3 and Peter Troke 4 * 1 Virginia Commonwealth University, Medical Centre, Richmond, VA, USA; 2 Health Protection Agency, Myrtle Road, Kingsdown, Bristol, UK; 3 Nevada Road, Hamilton 3216, New Zealand; 4 The Old Court, Kingsgate, CT10 3LW Kent, UK Received 3 October 2007; returned 9 November 2007; revised 26 November 2007; accepted 5 December 2007 Introduction: Fungal pathogens from the voriconazole trials were identified and tested for susceptibility at two reference laboratories. Methods: MICs were measured using CLSI M38-A 48 h microdilution methodology. Results: Moulds from 29 genera and 38 species were isolated from 18 countries. Aspergillus spp. predominated (69%), followed by Scedosporium spp. (11.5%). Aspergillus fumigatus (292/590, 49.5%) was the most common species, followed by Scediosporium apiospermum (9.7%) and Aspergillus terreus (7.3%). The bronchi, lungs and sinuses yielded 45% of the isolates (57% of aspergilli), with 24% from the oropharynx/oesophagus. Other sites included blood/catheter (7.3%) and CNS (5.2%). MIC 90 s of itraconazole and voriconazole for Aspergillus spp. were the same (0.5 mg/l), but 17 Aspergillus isolates were itraconazole-resistant (MICs 1 16 mg/l). Additionally, in 31 A. fumigatus and 23 A. terreus isolates, amphotericin MICs were 2.0 mg/l. Voriconazole MICs exceeded 4 mg/l in only 5.8% (34/590) of the isolates, including one A. fumigatus (8.0 mg/l), 9/11 Scedosporium prolificans, 10/13 Fusarium solani and all 9 Zygomycetes. Most were also not susceptible to itraconazole or amphotericin B. A notable increase in MIC (more than two doubling dilutions) during voriconazole therapy was seen for one A. fumigatus isolate. The response rate of voriconazole-treated patients with isolate MICs 4.0 mg/l was 38% when compared with 52% for those with MICs <4.0 mg/l. Conclusions: Voriconazole shows activity, in vitro, similar to that of itraconazole against a wide range of moulds. It is also active against some isolates not susceptible to itraconazole or amphotericin B, but not the Zygomycetes. The relationship between voriconazole MIC and clinical outcome requires further study. Keywords: Aspergillus, Scedosporium, Fusarium, Zygomycetes, MIC, clinical outcome Introduction Voriconazole is a wide-spectrum triazole antifungal agent that is approved for treating a range of fungal infections including those caused by the moulds Aspergillus, Scedosporium and Fusarium. There is an extensive literature detailing the in vitro susceptibility of fungi to voriconazole. 1 9 However, there are few data and mostly from case reports, examining the susceptibility of clinical mould isolates from patients treated with voriconazole The aim of the in vitro study reported here was to examine the worldwide susceptibility of moulds to voriconazole in comparison with the standard agents such as itraconazole and amphotericin B, to monitor for resistance during therapy and to examine any relationship between MIC and clinical response. Data for some of these isolates have been reported previously. 11 Methods The Voriconazole Mycology Reference Laboratories (A. E.-I., in Richmond, Virginia, USA and E. J. in Bristol, UK) confirmed isolate identity using standard methods and conducted susceptibility testing on 590 mould isolates from 323 patients included in the... *Corresponding author. Tel: þ ; peter2troke@btinternet.com # The Author Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please journals.permissions@oxfordjournals.org
2 Activities of voriconazole, itraconazole and amphotericin B Pfizer-sponsored, VCR Phase III global clinical studies and compassionate programmes as of October Both reference laboratories used the CLSI MIC method M38-A for moulds in its microdilution format. 21 Test strains were regularly exchanged between the two laboratories to ensure that their results were compatible. As no CLSI standard moulds were available at the time, the studies were conducted, and two Aspergillus fumigatus QC standards from the UK National Collection of Pathogenic Fungi (NCPF 7097 and NCPF 7100) were used on each test plate instead. Results Moulds from 29 genera and 38 species were isolated from 323 patients in 18 countries and 6 continents. However, most patients (71.8%) came from the USA, France and Germany. For those isolates where the numbers were large enough (Aspergillus spp. and Scedosporium spp.), there was no evidence for a significant impact of country of origin on MIC (data not shown). The most common predisposing underlying conditions were bone marrow or peripheral stem cell transplantation (32%), haematological malignancy (19%), solid organ transplantation (11%) and AIDS (9%). Most of the 590 isolates were from the bronchi, lungs or sinuses (45% overall, but 57% of the aspergilli) (Table 1). Other sites included the oropharynx/oesophagus (23%), blood/catheter (7.3%), brain/csf (5.2%) and bone, eye, liver, spleen, skin nodules and thyroid (9.0% in total). The majority of the isolates (57%) came from patients who had failed or been intolerant to prior antifungal therapies, whereas 43% came from primary therapy studies. Figure 1 shows the distribution of voriconazole, itraconazole and amphotericin B MIC values for all isolates tested, irrespective of genus. The MIC 90 s of both voriconazole and itraconazole were 1.0 mg/l and their MIC 50 s were 0.25 mg/l, whereas the corresponding values for amphotericin B were 4.0 and 1.0 mg/l, respectively. Aspergillus spp. accounted for 69% (409/590) of all mould isolates (A. fumigatus 49%, Aspergillus terreus 7.3% and Aspergillus flavus 6.1%). Scediosporium apiospermum (9.7%) was the most commonly isolated species, followed by Penicillium marneffei (5.8%; Table 2). Minor isolates (three or fewer) are given in Table 3. The voriconazole MICs for Aspergillus spp. ranged from 0.03 to 8.0 mg/l (MIC mg/l). In only a single Aspergillus Table 1. Major body sites of the mould isolates Body site Moulds (n) Bronchi (bronchoalveolar lavage) 148 Oropharynx/oesophagus 135 Lung/sinuses (biopsy) 120 Other deep biopsies a 68 Skin, skin nodules, pus 44 Blood/catheter 43 Other sites b 33 a Brain, bone, liver, stomach wall, spleen, thyroid, lymph node and eye. b Faeces, nasal swabs, open wounds, unknown (7). Figure 1. Distribution of voriconazole MICs for all mould isolates. VCR, voriconazole; ITR, itraconazole; AMB, amphotericin B. isolate (A. fumigatus) did the MIC exceed 2.0 mg/l. This isolate also had a raised MIC of itraconazole (MIC range mg/ L). However, 17 Aspergillus isolates were itraconazole resistant (MICs 1 16 mg/l). Additionally, 31 A. fumigatus and 23 A. terreus isolates had amphotericin MICs 2.0 mg/l. Scedosporium prolificans (MIC range mg/l) and various Fusarium spp. (MIC range mg/l) also yielded isolates with voriconazole MICs above the MIC 90 (Table 3). The few biphasic moulds (50 isolates) included in the database (Blastomyces dermatiditis, Histoplasma capsulatum, Paracoccidioides brasiliensis and P. marneffei) were all highly susceptible to voriconazole (Tables 2 and 3). The voriconazole, itraconazole and amphotericin B MICs for the 18 infrequently isolated genera including species of Acremonium, Alternaria, Blastomyces, Cladosporium, Curvularia, Cylindrocarpon, Exophiala, Fonsecaea, Microascus, Mycoleptodiscus, Neosartorya, Penicillium, Phialophora, Phoma, Pithomyces, Scopulariopsis, Trichoderma and Wangiella are given in Table 3. Voriconazole MICs were 2.0 mg/l for all isolates, except Scopulariopsis brevicaulis. In contrast, in 9 of these 18 isolates, itraconazole MICs were 2.0 mg/l, whereas in 12 of 18, amphotericin MICs were 2.0 mg/l. Among the 34 isolates with voriconazole MICs 4 mg/l (the resistance value established for yeasts by Pfaller et al. 22 ) were all 9 Zygomycetes (Absidia, Cunninghamella, Mucor, Rhizomucor and Rhizopus: MICs mg/l), 10/13 Fusarium solani, 9/11 S. prolificans, 1 A. fumigatus, 1 Fusarium oxysporum, 1Fusarium proliferatum, 1Microascus cinereus, 1 S. apiospermum and 1 S. brevicaulis. However, 32 of 33 isolates also had MICs of itraconazole 1.0 mg/l and 26 of 34 had MICs of amphotericin B 2.0 mg/l. In total, 55 patients had 82 isolates from 16 genera, which were itraconazole resistant (Tables 2 and 3). There were 24 patients with high voriconazole MIC isolates (including 7 with a zygomycete) occurring at baseline or at some time during voriconazole therapy, plus an assessment of clinical efficacy. These patients showed a reduced clinical response rate (38%) to voriconazole therapy when compared with the 202 voriconazole-treated patients with clinical isolates with voriconazole MICs,4.0 mg/l (52% response). In 37 patients, multiple cultures of 38 isolates were obtained during voriconazole therapy [21 Aspergillus spp. (A. flavus, 617
3 Espinel-Ingroff et al. Table 2. Most commonly isolated mould spp. susceptibility of clinical isolates to voriconazole and standard agents MIC range [IC 50 ] (IC 90 ) mg/l Isolates (n) voriconazole itraconazole amphotericin B A. flavus (36) [0.5] (0.5) [0.0078] (0.25) [1.0] (2.0) A. fumigatus (292) [0.25] (0.5) [0.25] (0.5) [1.0] (2.0) A. nidulans (13) [0.12] (0.12) [0.125] (0.25) [1.0] (2.0) Aspergillus niger (21) [0.31] (0.5) [0.05] (0.5) [0.5] (1.0) A. terreus (43) [025] (0.5) [0.062] (0.25) [2.0] (2.0) Aspergillus spp. (4) a Fusarium moniliforme (5) F. solani (13) [8.0] (16.0) [16.0] (16.0) [2.0] (4.0) Fusarium spp. (3) b H. capsulatum (5) P. lilacinus (5) P. brasiliensis (10) [0.0039] (0.035) [0.008] (0.03) [0.0125] (0.5) P. marneffei (34) [0.003] (0.003) [0.03] (0.03) [1.0] (1.0) S. apiospermum (57) [0.25] (0.25) [0.5] (1.0) [4.0] (8.0) S. prolificans (11) [4.0] (8.0) [16.0] (16.0) [16.0] (16.0) Zygomycetes (9) a Aspergillus glaucus (2), Aspergillus sydowii (1) and Aspergillus versicolor (1). b Fusarium incarnatum (1), F. oxysporum (1), F. proliferatum (1). Zygomycetes ¼ Absidia corymbifera (2), Cunninghamella bertholetiae (2), Mucor racemosus (1), Rhizomucor pusillus (1), Rhizopus arrhizus (1) and Rhizopus microsporus (2). A. fumigatus, Aspergillus nidulans and A. terreus), 7 S. apiospermum, 3P. marneffei, 2F. solani, 2P. brasiliensis, 1 Cylindrocarpon lichenicola, 1 Fonsecaea pedrosoi and 1 Paecilomyces lilacinus]. In 20 of 37 patients, therapy exceeded 15 days (range days, median 71 days). A notable (more than two doubling dilutions) MIC increase during therapy was detected for a single A. fumigatus isolate, obtained via sequential lung biopsies from a patient with pulmonary aspergillosis. After Table 3. Minor mould spp. susceptibility of clinical isolates to voriconazole and standard agents MIC range (mg/l) Isolates (n) voriconazole itraconazole amphotericin B Acremonium sp. (1) Alternaria sp. (4) B. dermatiditis (1) Cladosporium cladosporiodes (1) Curvularia sp. (1) C. lichenicola (3) Exophiala spinifera (1) F. pedrosoi (4) M. cinereus (1) Mycoleptodiscus indicus (2) Neosartorya fischeri (1) Penicillium verrucosum (1) Phialophora parasitica (1) Phialophora richardsiae (1) Phoma sp. (1) Pithomyces sp. (2) Scopulariopsis brevicaulis (1) Trichoderma sp. (1) Wangiella dermatiditis (1)
4 Activities of voriconazole, itraconazole and amphotericin B 148 days of therapy, the voriconazole MIC had increased 16-fold from 0.5 to 8.0 mg/l and the patient failed therapy. The isolate also became cross-resistant to itraconazole (MIC increase from 0.25 mg/l at baseline to 4.0 mg/l). Conclusions Voriconazole was highly potent in vitro against the majority of clinical isolates from the Phase III studies. These MIC results are consistent with the published data for recent isolate collections and case studies However, as has been established previously, the zygomycete isolates were not susceptible to voriconazole In general, the in vitro activity of voriconazole against the moulds in this study was comparable with that of itraconazole and somewhat better than amphotericin B. The voriconazole susceptibility ranges for the Fusarium species, especially F. solani, and S. prolificans were wide, which suggests that elevated dose levels of voriconazole or even combination therapy should be considered to treat these lesssusceptible but potentially severe infections. 26,27 However, outcome data suggest that voriconazole therapy alone may be successful in some cases. 11,28 Resistance development during long-term voriconazole therapy was detected in a single A. fumigatus isolate and this patient failed therapy. Unlike the yeasts, 22 a correlation between voriconazole mould MICs and clinical outcome remains to be established. Many of the patients in this analysis were neutropenic or had other significant immune deficits, and the overall response rate to voriconazole therapy was less than that for yeasts. 22 However, based on the current breakpoints for Candida spp. 21 and recent in vitro data for moulds, 30 plus the achievable voriconazole exposure in adults (6 mg/kg iv 12 hourly loading dose on day 1 then 4 mg/kg iv twice daily) and published efficacy against moulds, a 48 h resistance breakpoint of 4 mg/l might represent a suitable initial, experimental 11,28 30 value. Funding The data for this manuscript were generated during Pfizer-sponsored, Phase III clinical trials. Both P. T. and H. H. received funding from Pfizer in connection with the development of this manuscript. E. J. and A. E.-I. received funding from Pfizer to run the voriconazole mycological reference laboratories. Transparency declarations P. T. owns shares in, was previously an employee of, and is currently a consultant to Pfizer. He is also a consultant to and a share owner of Cytomics and has received honoraria from Rothschilds and F2G. H. H. is a statistical consultant to Pfizer. E. J. and A. E.-I. received funding from Pfizer to attend relevant conferences during the study period. E. J. has also received honoraria from Gilead, MSD, Ortho-Biotech, Pfizer, Schering-Plough and Zeneus. References 1. Espinel-Ingroff A, Boyle K, Sheehan DJ. In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature. Mycopathologia 2001; 150: Pfaller MA, Messer SA, Hollis RJ et al. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY antimicrobial surveillance program, Antimicrob Agents Chemother 2002; 46: Pfaller MA, Messer SA, Boyken L et al. In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagn Microbiol Infect Dis 2004; 48: Pfaller MA, Messer SA, Hollis RJ et al. In vitro susceptibility testing of Aspergillus spp: comparison of E-test and reference microdilution methods for determining voriconazole and itraconazole MICs. J Clin Microbiol 2003; 41: Diekema DJ, Messer SA, Hollis RJ et al. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol 2003; 41: Marangon FB, Miller D, Giaconi JA et al. In vitro investigation of voriconazole susceptibility for keratitis and endophthalmitis fungal pathogens. Am J Ophthalmol 2004; 137: Morace G, Polonelli L. Voriconazole activity against clinical yeast isolates: a multicentre Italian study. Int J Antimicrob Agents 2005; 26: Peman J, Jarque I, Bosch M et al. Spondylodiscitis caused by Candida krusei: case report and susceptibility patterns. J Clin Microbiol 2006; 44: Sabatelli F, Patel R, Mann PA et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important moulds and yeasts. Antimicrob Agents Chemother 2006; 50: Girmenia C, Lutzi G, Monaco M et al. Use of voriconazole in treatment of Scedosporium apiospermum infection: case report. J Clin Microbiol 1998; 36: Perfect JR, Marr KA, Walsh TJ et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003; 36: Studahl M, Backteman T, Stalhammar F et al. Bone and joint infection after traumatic implantation of Scedosporium prolificans treated with voriconazole and surgery. Acta Paediatr 2003; 92: Bosma F, Voss A, van Hammersvelt HW et al. Two cases of subcutaneous Scedosporium apiospermum infection treated with voriconazole. Clin Microbiol Infect 2003; 9: Nulens E, Eggink C, Rijs AJ et al. Keratitis caused by Scedosporium apiospermum successfully treated with a cornea transplant and voriconazole. J Clin Microbiol 2003; 41: Lyons MK, Blair JE, Leslie KO. Successful treatment with voriconazole of fungal cerebral abscess due to Cladophialophora bantiana. Clin Neurol Neurosurg 2005; 107: Proia LA, Tenorio AR. Successful use of voriconazole for treatment of Coccidioides meningitis. Antimicrob Agents Chemother 2004; 48: Chamilos G, Kontoyiannis DP. Voriconazole-resistant disseminated Paecilomyces variotii infection in a neutropenic patient with leukaemia on voriconazole prophylaxis. J Infect 2005; 51: e Schaenman JM, Digiulio DB, Mirrels LF et al. Scedosporium apiospermum soft tissue infection successfully treated with 619
5 Espinel-Ingroff et al. voriconazole: potential pitfalls in the transition from intravenous to oral therapy. J Clin Microbiol 2005; 43: Schwartz S, Ruhnke M, Ribaud P et al. Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood 2005; 106: Ozbek Z, Kang S, Sivalingam J et al. Voriconazole in the management of Alternaria keratitis. Cornea 2006; 25: Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Moulds: Approved Standard M38-A. CLSI, Villanova, PA, USA, Pfaller MA, Diekema DJ, Rex JH et al. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J Clin Microbiol 2006; 44: Sun QN, Fothergill AW, McArthy DI et al. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of Zygomycetes. Antimicrob Agents Chemother 2002; 46: Dannaoui E, Meletiadis J, Mouton JW et al. In vitro susceptibilities of Zygomycetes to conventional and new antifungals. J Antimicrob Chemother 2003; 51: Chayakulkeeree M, Ghannoum MA, Perfect JR. Zygomycosis: the re-emerging fungal infection. Eur J Clin Microbiol Infect Dis 2006; 24: Ortoneda M, Capilla J, Javier Pastor F et al. In vitro interactions of licensed and novel antifungal drugs against Fusarium spp. Diagn Microbiol Infect Dis 2004; 48: Meletiadis J, Mouton JW, Meis JF et al. In vitro drug interaction modelling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates. Antimicrob Agents Chemother 2003; 47: Baden L, Katz J, Fischman J et al. Salvage therapy with voriconazole for invasive fungal infections in patients failing or intolerant of standard antifungal therapy. Transplantation 2003; 76: Herbrecht H, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: Espinel-Ingroff A, Arthington-Skaggs N, Ellis D et al. Multicenter evaluation of a new disk agar diffusion method for susceptibility testing of filamentous fungi against voriconazole, posaconazole, itraconazole, amphotericin B and caspofungin. JClinMicrobiol 2007; 45:
on November 3, 2018 by guest
JOURNAL OF CLINICAL MICROBIOLOGY, June 2007, p. 1811 1820 Vol. 45, No. 6 0095-1137/07/$08.00 0 doi:10.1128/jcm.00134-07 Copyright 2007, American Society for Microbiology. All Rights Reserved. Multicenter
More informationAUSTRALIAN ANTIFUNGAL SUSCEPTIBILITY DATA : PART 2 THE MOULDS ASPERGILLUS, SCEDOSPORIUM AND FUSARIUM.
AUSTRALIAN ANTIFUNGAL SUSCEPTIBILITY DATA 00-0: PART THE MOULDS ASPERGILLUS, SCEDOSPORIUM AND FUSARIUM. AUSTRALIAN Sarah Kidd, Rose Handke and ANTIFUNGAL David Ellis SUSCEPTIBILITY DATA 00-00 David SA
More informationVoriconazole. Voriconazole VRCZ ITCZ
7 7 8 7 8 fluconazole itraconazole in vitro in vivo Candida spp. C. glabrata C. krusei Cryptococcus neoformans in vitro Aspergillus spp. in vitro in vivo Aspergillus fumigatus Candida albicans C. krusei
More informationAbout the Editor Gerri S. Hall, Ph.D.
About the Editor Gerri S. Hall, Ph.D. Dr. Hall s professional career has been focused on clinical microbiology: direct clinical activities of various areas such as bacteriology, mycobacteria, STD testing,
More informationTreatment of rare and emerging fungal infections. EFISG Educational Workshop 15 th ECCMID April 2, 2005, Copenhagen
Treatment of rare and emerging fungal infections EFISG Educational Workshop 15 th ECCMID April 2, 2005, Copenhagen Helen Sambatakou Lecturer in Medicine and Infectious Diseases, University of Athens, Greece
More informationAntifungal Susceptibility Testing
Infect Dis Clin N Am 20 (2006) 699 709 Antifungal Susceptibility Testing Annette W. Fothergill, MA, MBA, MT(ASCP), CLS(NCA) a, Michael G. Rinaldi, PhD a,b, Deanna A. Sutton, PhD, MT, SM(ASCP), SM, RM(NRM)
More informationReceived 18 December 2008/Returned for modification 9 February 2009/Accepted 9 April 2009
JOURNAL OF CLINICAL MICROBIOLOGY, June 2009, p. 1942 1946 Vol. 47, No. 6 0095-1137/09/$08.00 0 doi:10.1128/jcm.02434-08 Copyright 2009, American Society for Microbiology. All Rights Reserved. Activity
More informationReceived 22 November 2007/Returned for modification 29 December 2007/Accepted 12 January 2008
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 2008, p. 1396 1400 Vol. 52, No. 4 0066-4804/08/$08.00 0 doi:10.1128/aac.01512-07 Copyright 2008, American Society for Microbiology. All Rights Reserved. In Vitro
More informationAntifungal Activity of Voriconazole on Local Isolates: an In-vitro Study
Original Article Philippine Journal of OPHTHALMOLOGY Antifungal Activity of Voriconazole on Local Isolates: an In-vitro Study Karina Q. De Sagun-Bella, MD, 1 Archimedes Lee D. Agahan, MD, 1 Leo DP. Cubillan,
More informationAAC Accepts, published online ahead of print on 21 March 2011 Antimicrob. Agents Chemother. doi: /aac
AAC Accepts, published online ahead of print on 1 March 0 Antimicrob. Agents Chemother. doi:./aac.010- Copyright 0, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationyour lab focus susceptibility testing of yeasts and moulds as well as the clinical implications of in vitro antifungal testing.
626 CE update [microbiology and virology] Antifungal Susceptibility Methods and Their Potential Clinical Relevance Ana Espinel-Ingroff, PhD Medical College of Virginia, Virginia Commonwealth University,
More informationTable 1. Antifungal Breakpoints for Candida. 2,3. Agent S SDD or I R. Fluconazole < 8.0 mg/ml mg/ml. > 64 mg/ml.
AUSTRALIAN ANTIFUNGAL SUSCEPTIBILITY DATA 2008-2011 Part 1: The Yeasts In this article, an update of recent changes to the CLSI antifungal standards for susceptibility testing of yeasts is presented. We
More informationReceived 26 July 2006/Returned for modification 10 October 2006/Accepted 16 October 2006
JOURNAL OF CLINICAL MICROBIOLOGY, Jan. 2007, p. 70 75 Vol. 45, No. 1 0095-1137/07/$08.00 0 doi:10.1128/jcm.01551-06 Copyright 2007, American Society for Microbiology. All Rights Reserved. Use of Fluconazole
More informationReceived 31 March 2009/Returned for modification 26 May 2009/Accepted 22 June 2009
JOURNAL OF CLINICAL MICROBIOLOGY, Sept. 2009, p. 2766 2771 Vol. 47, No. 9 0095-1137/09/$08.00 0 doi:10.1128/jcm.00654-09 Copyright 2009, American Society for Microbiology. All Rights Reserved. Comparison
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Voriconazole Effective Date... 3/15/2018 Next Review Date... 3/15/2019 Coverage Policy Number... 4004 Table of Contents Coverage Policy... 1 General Background...
More informationANA ESPINEL-INGROFF* Division of Infectious Diseases, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia
JOURNAL OF CLINICAL MICROBIOLOGY, Jan. 1998, p. 198 202 Vol. 36, No. 1 0095-1137/98/$04.00 0 Copyright 1998, American Society for Microbiology In Vitro Activity of the New Triazole Voriconazole (UK-109,496)
More informationNew triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance
For reprint orders, please contact reprints@expert-reviews.com New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance Expert Rev. Anti Infect. Ther. 7(8), 981 998
More informationReceived 7 March 2002/Returned for modification 16 April 2002/Accepted 13 June 2002
JOURNAL OF CLINICAL MICROBIOLOGY, Sept. 2002, p. 3204 3208 Vol. 40, No. 9 0095-1137/02/$04.00 0 DOI: 10.1128/JCM.40.9.3204 3208.2002 Copyright 2002, American Society for Microbiology. All Rights Reserved.
More informationAntifungal Pharmacodynamics A Strategy to Optimize Efficacy
Antifungal Pharmacodynamics A Strategy to Optimize Efficacy David Andes, MD Associate Professor, Department of Medicine Division of Infectious Diseases Medical Microbiology and Immunology University of
More informationNo Evidence As Yet. Georg Maschmeyer. Dept. of Hematology, Oncology & Palliative Care Klinikum Ernst von Bergmann Potsdam, Germany
Is Combined Antifungal Therapy More Efficient than Single Agent Therapy? No Evidence As Yet www.ichs.org Georg Maschmeyer Dept. of Hematology, Oncology & Palliative Care Klinikum Ernst von Bergmann Potsdam,
More informationUse of Antifungal Drugs in the Year 2006"
Use of Antifungal Drugs in the Year 2006" Jose G. Montoya, MD Associate Professor of Medicine Associate Chief for Clinical Affairs Division of Infectious Diseases Stanford University School of Medicine
More informationThe incidence of invasive fungal infections
AN EPIDEMIOLOGIC UPDATE ON INVASIVE FUNGAL INFECTIONS * Michael A. Pfaller, MD ABSTRACT *Based on a presentation given by Dr Pfaller at a symposium held in conjunction with the 43rd Interscience Conference
More informationUpdate zu EUCAST 2012 Cornelia Lass-Flörl
Update zu EUCAST 2012 Cornelia Lass-Flörl Frühjahrstagung 2012 Paul-Ehrlich-Gesellschaft Sektion Antimykotische Chemotherapie Bonn, 4./5. Mai 2012 Agenda 1. Breakpoints 2. Rationale documents and technical
More informationREVIEW. Changing epidemiology of systemic fungal infections M. Richardson 1 and C. Lass-Flörl 2
REVIEW Changing epidemiology of systemic fungal infections M. Richardson 1 and C. Lass-Flörl 2 1 Department of Bacteriology &Immunology, University of Helsinki, and Helsinki University Central Hospital
More informationReceived 13 September 2006/Returned for modification 6 November 2006/Accepted 26 December 2006
JOURNAL OF CLINICAL MICROBIOLOGY, Mar. 2007, p. 858 864 Vol. 45, No. 3 0095-1137/07/$08.00 0 doi:10.1128/jcm.01900-06 Copyright 2007, American Society for Microbiology. All Rights Reserved. Correlation
More informationIsavuconazole: A New Broad-Spectrum Triazole Antifungal Agent
REVIEWS OF ANTI-INFECTIVE AGENTS INVITED ARTICLE Louis D. Saravolatz, Section Editor Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent Marisa H. Miceli 1 and Carol A. Kauffman 1,2 1 Division
More informationFungal Infection Pre-Infusion Data
Fungal Infection Pre-Infusion Data Registry Use Only Sequence Number: Date Received: CIBMTR Center Number: Event date: / / CIBMTR Form 2046 revision 5 (page 1 of 5). Last Updated May, 2018. Infection Episode
More informationVoriconazole October 2015 Risk Management Plan. Voriconazole
Voriconazole October 2015 VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Invasive aspergillosis (IA) is the most devastating of Aspergillus related diseases, targeting severely
More informationDepartment of Pathology, University of Iowa College of Medicine, Iowa City, 1 and The JONES Group/JMI Laboratories, North Liberty, 2 Iowa
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 2002, p. 1032 1037 Vol. 46, No. 4 0066-4804/02/$04.00 0 DOI: 10.1128/AAC.46.4.1032 1037.2002 Copyright 2002, American Society for Microbiology. All Rights Reserved.
More informationUse of Antifungals in the Year 2008
Use of Antifungals in the Year 2008 Jose G. Montoya, MD Associate Professor of Medicine Associate Chief for Clinical Affairs Division of Infectious Diseases Stanford University School of Medicine Diagnosis
More informationIsolates from a Phase 3 Clinical Trial. of Medicine and College of Public Health, Iowa City, Iowa 52242, Wayne, Pennsylvania ,
JCM Accepts, published online ahead of print on 26 May 2010 J. Clin. Microbiol. doi:10.1128/jcm.00806-10 Copyright 2010, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationAspergillosis in the critically ill patient
Aspergillosis in the critically ill patient José Artur Paiva Director of Emergency and Intensive Care Department Centro Hospitalar São João Porto Associate Professor of Medicine University of Porto Infection
More informationInvasive aspergillosis (IA) has emerged as a major cause of morbidity. Aspergillus terreus
1594 Aspergillus terreus An Emerging Amphotericin B Resistant Opportunistic Mold in Patients with Hematologic Malignancies Ray Y. Hachem, M.D. 1 Dimitrios P. Kontoyiannis, M.D., Sc.D. 1 Maha R. Boktour,
More informationAmphotericin B, antifungal susceptibility, bloodstream infections, Candida spp., posaconazole, sus-
ORIGINAL ARTICLE 10.1111/j.1469-0691.2005.01310.x Epidemiology of candidaemia and antifungal susceptibility patterns in an Italian tertiary-care hospital A. Bedini 1, C. Venturelli 2, C. Mussini 1, G.
More informationNationwide survey of treatment for pediatric patients with invasive fungal infections in Japan
J Infect Chemother (2013) 19:946 950 DOI 10.1007/s10156-013-0624-7 ORIGINAL ARTICLE Nationwide survey of treatment for pediatric patients with invasive fungal infections in Japan Masaaki Mori Received:
More informationIn Vitro Studies with R 51,211 (Itraconazole)
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, JUIY 1984, p. 5-9 Vol. 26, No. 1 0066-4804/84/070005-05$02.00/0 Copyright 1984, American Society for Microbiology In Vitro Studies with R 51,211 (Itraconazole) ANA
More informationFungal Infection Post-Infusion Data
Fungal Infection Post-Infusion Data Registry Use Only Sequence Number: Date Received: CIBMTR Center Number: Event date: / / Visit: 100 day 6 months 1 year 2 years >2 years. Specify: CIBMTR Form 2146 revision
More informationJapan Antifungal Surveillance Program (1):
183 Japan Antifungal Surveillance Program (1): 2001 2002 1) 1) 2) 3) 4) 5) 6) 7) 8) 9) 10) 11) 12) 1) 1) 2) 3) 4) 5) 6) 7) 8) 9) 10) 11) 12) 16 9 14 16 10 12 2001 6 2002 3 2 11 576 fluconazole (FLCZ),
More informationInsights into Antifungal Resistance & Newer (Other) Moulds
Insights into Antifungal Resistance & Newer (Other) Moulds Nathan P. Wiederhold, PharmD Fungus Testing Laboratory (FTL) Department of Pathology & Laboratory Medicine South Texas Reference Laboratories
More informationAntifungal Agents - Cresemba (isavuconazonium), Vfend. Prior Authorization Program Summary
Antifungal Agents - Cresemba (isavuconazonium), Noxafil (posaconazole), Vfend (voriconazole) Prior Authorization Program Summary FDA APPROVED INDICATIONS DOSAGE 1,2,14 Drug FDA Indication(s) Dosing Cresemba
More informationFungal infections in ICU. Tang Swee Fong Department of Paediatrics Universiti Kebangsaan Malaysia
Fungal infections in ICU Tang Swee Fong Department of Paediatrics Universiti Kebangsaan Malaysia Epidemiology of invasive fungal infections - US +300% Martin GS, et al. N Engl J Med 2003;348:1546-1554
More informationIt is well known that patient populations at risk for serious. Voriconazole: A New Triazole Antifungal Agent. Formulary Forum
Formulary Forum Voriconazole: A New Triazole Antifungal Agent Margaret M Pearson, P David Rogers, John D Cleary, and Stanley W Chapman OBJECTIVE: To review the pharmacology, in vitro susceptibility, pharmacokinetics,
More informationReview. Ana Espinel-Ingroff
Review Rev Iberoam Micol 2003; 20: 121-136 121 In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods
More informationAntifungal Pharmacotherapy
Interpreting Antifungal Susceptibility Testing: Science or Smoke and Mirrors A. W. F O T H E R G I L L, M A, M B A U N I V E R S I T Y O F T E X A S H E A L T H S C I E N C E C E N T E R S A N A N T O
More informationHAEMATOLOGY ANTIFUNGAL POLICY
HAEMATOLOGY ANTIFUNGAL POLICY PROPHYLAXIS Primary Prophylaxis Patient Group Patients receiving intensive remissioninduction chemotherapy for Acute Leukaemia (excluding patients receiving vinca alkaloids)
More informationVoriconazole Rationale for the EUCAST clinical breakpoints, version March 2010
Voriconazole Rationale for the EUCAST clinical breakpoints, version 2.0 20 March 2010 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised by the European
More informationTreatment Guidelines for Invasive Aspergillosis
Treatment Guidelines for Invasive Aspergillosis Thomas F. Patterson, MD Professor of Medicine Director, San Antonio Center for Medical Mycology The University of Texas Health Science Center at San Antonio
More informationLABORATORY SCIENCES. Antimicrobial Susceptibility of Fusarium, Aspergillus, and Other Filamentous Fungi Isolated From Keratitis
LABORATORY SCIENCES Antimicrobial Susceptibility of Fusarium, Aspergillus, and Other Filamentous Fungi Isolated From Keratitis Prajna Lalitha, MD; Brett L. Shapiro, BA; Muthiah Srinivasan, MD; Namperumalsamy
More informationNew and Investigational Triazole Agents for the Treatment of Invasive Fungal Infections
REPRINT Journal of Chemotherapy Vol. 20 - n. 6 (51-?) - 2008 REVIEW New and Investigational Triazole Agents for the Treatment of Invasive Fungal Infections A. DE SARRO 1 - E. LA CAMERA 2 - M.T. FERA 2
More informationMANAGEMENT OF HOSPITAL-ACQUIRED FUNGAL INFECTIONS
MANAGEMENT OF HOSPITAL-ACQUIRED FUNGAL INFECTIONS Paul D. Holtom, MD Associate Professor of Medicine and Orthopaedics USC Keck School of Medicine Numbers of Cases of Sepsis in the United States, According
More informationMycology Review. Background. Background. Specimen Collection. Calcofluor White. Methods. Yeasts. Moulds. Melissa B. Miller, Ph.D.
Background Mycology Review Melissa B. Miller, Ph.D. April 4, 2008 Yeasts Unicellular Divide by budding or binary fission Moulds Filamentous hyphae interweave to form mycelium Saprobic phase: airborne,
More informationPattern of Antifungal Susceptibility in Pathogenic Molds by Microdilution Method at a Tertiary Care Hospital
Original Article Pattern of Antifungal Susceptibility in Pathogenic Molds by Microdilution Method at a Tertiary Care Hospital Maria Khan*, Aamer Ikram, Gohar Zaman, Adeel Gardezi and Farida Khurram Lalani
More informationThermotolerant filamentous fungi in belgian hospitals: 15 years of survey
BVMDM-SBMHA, November 14, 2013- Ophain Françoise SYMOENS Thermotolerant filamentous fungi in belgian hospitals: 15 years of survey Fungi in hospitals (species and amount) Different settings/context Analyse
More informationFilamentous fungi MALDI-TOF identification
Filamentous fungi MALDI-TOF identification Stéphane Ranque Parasitologie & Mycologie AP-HM Timone Marseille, France stephane.ranque@ap-hm.fr Aspergillus flavus Aspergillus ochraceus Conidia 3 to 6 µ Conidia
More informationNew Directions in Invasive Fungal Disease: Therapeutic Considerations
New Directions in Invasive Fungal Disease: Therapeutic Considerations Coleman Rotstein, MD, FRCPC, FACP University of Toronto University Health Network Toronto, Ontario Disclosure Statement for Coleman
More informationTherapy of Hematologic Malignancies Period at high risk of IFI
Therapy of Hematologic Malignancies Period at high risk of IFI Neutrophils (/mm 3 ) 5 Chemotherapy Conditioning Regimen HSCT Engraftment GVHD + Immunosuppressive Treatment Cutaneous and mucositis : - Direct
More informationProphylaxis versus Diagnostics-driven approaches to treatment of Invasive fungal diseases. Y.L. Kwong Department of Medicine University of Hong Kong
Prophylaxis versus Diagnostics-driven approaches to treatment of Invasive fungal diseases Y.L. Kwong Department of Medicine University of Hong Kong Pathogenic yeast Candida Cryptococcus Trichosporon Pathogenic
More informationEfficacy of amphotericin B at suboptimal dose combined with. voriconazole in a murine infection by Aspergillus fumigatus with poor in
AAC Accepts, published online ahead of print on 24 June 2013 Antimicrob. Agents Chemother. doi:10.1128/aac.00563-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 2 3 4 5 6 7
More informationEchinocandin and triazole antifungal susceptibility profiles of opportunistic yeast and mould clinical
JCM Accepts, published online ahead of print on 29 May 2013 J. Clin. Microbiol. doi:10.1128/jcm.00308-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 2 3 4 JCM00308-13 REVISION
More informationPROGRESSI NELLA TERAPIA ANTIFUNGINA. A tribute to Piero Martino
PROGRESSI NELLA TERAPIA ANTIFUNGINA A tribute to Piero Martino 1946-2007 ITALIAN ICONS IERI, OGGI, E DOMANI IERI, OGGI, E DOMANI IERI, OGGI, E DOMANI 1961 CAUSES OF DEATH IN PATIENTS WITH MALIGNANCIES
More informationMycology. BioV 400. Subcutaneous Mycoses. Ecological associations. Geographic distribution World-wide
BioV 400 Mycology Handout 8 Subcutaneous Mycoses Lymphocutaneous sporotrichosis Chromoblastomycosis Phaeohyphomycosis Zygomycosis Mycetoma Lymphocutaneous sporotrichosis Sporothrix schenckii Chronic infection
More informationon December 11, 2018 by guest
JCM Accepts, published online ahead of print on 12 December 2012 J. Clin. Microbiol. doi:10.1128/jcm.03125-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 Biographical Feature;
More informationMonitorization, Separation and Quantification of Antifungals used for Invasive Aspergillosis Treatment by High Performance Thin Layer Chromatography
Monitorization, Separation and Quantification of Antifungals used for Invasive Aspergillosis Treatment by High Performance Thin Layer Chromatography M. P. Domingo, M. Vidal, J. Pardo, A. Rezusta, L. Roc,
More informationResistance epidemiology
ECMM/EFISG symposium: Multidrug resistance in fungi? A formidable foe Resistance epidemiology Ana Alastruey Izquierdo Mycology Reference Lab Spain Instituto de Salud Carlos III Disclousure I have received
More informationReceived 25 September 2006/Returned for modification 4 December 2006/Accepted 26 December 2006
JOURNAL OF CLINICAL MICROBIOLOGY, Mar. 2007, p. 796 802 Vol. 45, No. 3 0095-1137/07/$08.00 0 doi:10.1128/jcm.01986-06 Copyright 2007, American Society for Microbiology. All Rights Reserved. Multicenter
More informationHow Can We Prevent Invasive Fungal Disease?
How Can We Prevent Invasive Fungal Disease? Chris Kibbler Professor of Medical Microbiology University College London And Royal Free Hospital, London, UK Invasive Aspergillosis 2 - Acquisition Preventive
More informationMicafungin and Candida spp. Rationale for the EUCAST clinical breakpoints. Version February 2013
Micafungin and Candida spp. Rationale for the EUCAST clinical breakpoints. Version 1.0 5 February 2013 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised
More informationComparison of microdilution method and E-test procedure in susceptibility testing of caspofungin against Candida non-albicans species
NEW MICROBIOLOGICA, 31, 257-262, 2008 Comparison of microdilution method and E-test procedure in susceptibility testing of caspofungin against Candida non-albicans species Anna Serefko, Renata Los, Anna
More informationAntifungal Update. Candida: In Vitro Antifungal Susceptibility Testing
Antifungal Update B. Joseph Guglielmo, Pharm.D. Professor and Chair Department of Clinical Pharmacy School of Pharmacy University of California San Francisco The patient spikes a new fever and 3/3 blood
More informationIn vitro Combination Therapy of Isavuconazole against Medically Important., Thomas J. Walsh
AAC Accepts, published online ahead of print on 18 August 2014 Antimicrob. Agents Chemother. doi:10.1128/aac.03261-14 Copyright 2014, American Society for Microbiology. All Rights Reserved. 1 2 In vitro
More informationInterpretive Breakpoints for Fluconazole and Candida Revisited: a Blueprint for the Future of Antifungal Susceptibility Testing
CLINICAL MICROBIOLOGY REVIEWS, Apr. 2006, p. 435 447 Vol. 19, No. 2 0893-8512/06/$08.00 0 doi:10.1128/cmr.19.2.435 447.2006 Copyright 2006, American Society for Microbiology. All Rights Reserved. Interpretive
More informationAntifungal Resistance in Asia: Mechanisms, Epidemiology, and Consequences
5th MMTN Conference 5-6 November 2016 Bangkok, Thailand 10:20-10:45, 6 Nov, 2016 Antifungal Resistance in Asia: Mechanisms, Epidemiology, and Consequences Yee-Chun Chen, M.D., PhD. Department of Medicine,
More informationSensitivity of Candida albicans isolates to caspofungin comparison of microdilution method and E-test procedure
Basic research Sensitivity of Candida albicans isolates to caspofungin comparison of microdilution method and E-test procedure Anna Serefko, Anna Malm Department of Pharmaceutical Microbiology, Medical
More informationHistopathology Description:
2013-2-1 CANINE HEART Ahmed M. Abubakar BOVINE PATHOLOGY CONTRIBUTING INSTITUTION : The Royal Veterinary college, Dept. of Pathology and Biology Signalment: 11-month-old male Border Collie dog (Canis familiaris)
More informationEpidemiology and Resistance in Aspergillus and other Moulds
Epidemiology and Resistance in Aspergillus and other Moulds Nathan Wiederhold, PharmD Associate Professor Director, Fungus Testing Laboratory Invasive Mould Infections Often opportunistic Associated with
More informationAn Update in the Management of Candidiasis
An Update in the Management of Candidiasis Daniel B. Chastain, Pharm.D., AAHIVP Infectious Diseases Pharmacy Specialist Phoebe Putney Memorial Hospital Adjunct Clinical Assistant Professor UGA College
More informationReceived 5 August 2004/Accepted 26 September 2004
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 2005, p. 512 517 Vol. 49, No. 2 0066-4804/05/$08.00 0 doi:10.1128/aac.49.2.512 517.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved.
More informationHormographiella aspergillata: an emerging mould in acute leukaemia patients?
ORIGINAL ARTICLE MYCOLOGY Hormographiella aspergillata: an emerging mould in acute leukaemia patients? A. Conen 1, M. Weisser 2, D. Hohler 3, R. Frei 3 and M. Stern 4 1) Division of Infectious Diseases
More informationCURRENT AND NEWER ANTI-FUNGAL THERAPIES- MECHANISMS, INDICATIONS, LIMITATIONS AND PROBLEMS. Dr AMIT RAODEO DM SEMINAR
CURRENT AND NEWER ANTI-FUNGAL THERAPIES- MECHANISMS, INDICATIONS, LIMITATIONS AND PROBLEMS Dr AMIT RAODEO DM SEMINAR Introduction The incidence of invasive fungal infections in critically ill intensive
More informationAntifungal Update 2/22/12. Which is the most appropriate initial empirical therapy in a candidemic patient?
Antifungal Update B. Joseph Guglielmo, Pharm.D. Professor and Chair Department of Clinical Pharmacy School of Pharmacy University of California San Francisco 3/3 blood cultures are positive for an unidentified
More informationMultilaboratory Testing of Two-Drug Combinations of Antifungals against Candida albicans, Candida glabrata, and Candida parapsilosis
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 2011, p. 1543 1548 Vol. 55, No. 4 0066-4804/11/$12.00 doi:10.1128/aac.01510-09 Copyright 2011, American Society for Microbiology. All Rights Reserved. Multilaboratory
More informationby author CNS Difficult-to-treat fungal infections Campus Benjamin Franklin Dep. of Hematology and oncology PD Dr. Stefan Schwartz
Difficult-to-treat fungal infections CNS Campus Benjamin Franklin Dep. of Hematology and oncology PD Dr. Stefan Schwartz ME161 ECCMID 2017, Vienna U N I V E R S I T Ä T S M E D I Z I N B E R L I N Types
More informationClinical Considerations in the Management of Systemic Fungal Infections. Conducted during the 41 st ASHP Midyear Clinical Meeting Anaheim, California
Clinical Considerations in the Management of Systemic Fungal Infections Conducted during the 41 st ASHP Midyear Clinical Meeting Anaheim, California CONTINUING EDUCATION ACCREDITATION The American Society
More informationFungal infections remain an important cause of morbidity
Pharmacology Notes Posaconazole (Noxafil): a new triazole antifungal agent Nickie D. Greer, PharmD, BCPS Posaconazole is the newest triazole antifungal agent. It is structurally related to itraconazole
More informationNew antifungal agents
New antifungal agents Dr Atul Patel, MD, FIDSA Chief Consultant and Director Infectious Diseases Clinic Vedanta Institute of Medical Sciences Ahmedabad, India Presented at MMTN Malaysia Conference 5 6
More informationADEQUATE ANTIFUNGAL USE FOR BLOODSTREAM INFECTIONS
ADEQUATE ANTIFUNGAL USE FOR BLOODSTREAM INFECTIONS COMMERCIAL RELATIONS DISCLOSURE 2500 9000 15000 Astellas Gilead Sciences Pfizer Inc Expert advice Speaker s bureau Speaker s bureau OUTLINE OF THE PRESENTATION
More informationIn Vitro Interactions of Antifungal agents and Tacrolimus against Aspergillus Biofilms
AAC Accepted Manuscript Posted Online 24 August 2015 Antimicrob. Agents Chemother. doi:10.1128/aac.01510-15 Copyright 2015, American Society for Microbiology. All Rights Reserved. 1 In Vitro Interactions
More informationAntifungals in Invasive Fungal Infections: Antifungals in neutropenic patients
BVIKM-SBIMC La Hulpe, 6 November 2008 Antifungals in Invasive Fungal Infections: Antifungals in neutropenic patients Johan Maertens, MD Acute Leukemia and SCT Unit University Hospital Gasthuisberg Catholic
More informationTreatment Guidelines for Invasive Aspergillosis
Treatment Guidelines for Invasive Aspergillosis Thomas F. Patterson, MD Professor of Medicine Director, San Antonio Center for Medical Mycology The University of Texas Health Science Center at San Antonio
More information1. Pre-emptive therapy. colonization, colonization, pre-emptive therapy. , ICU colonization. colonization. 2, C. albicans
Jpn. J. Med. Mycol. Vol. 45, 217 221, 2004 ISSN 0916 4804,.,, colonization, pre-emptive therapy. 2, non-albicans Candida., fluconazole.,. Key words: postoperative infection, non-albicans Candida, pre-emptive
More informationEfficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei
Journal of Antimicrobial Chemotherapy (2009) 63, 161 166 doi:10.1093/jac/dkn431 Advance Access publication 13 November 2008 Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic
More informationReceived 21 July 2008/Accepted 3 September 2008
JOURNAL OF CLINICAL MICROBIOLOGY, Nov. 2008, p. 3585 3590 Vol. 46, No. 11 0095-1137/08/$08.00 0 doi:10.1128/jcm.01391-08 Copyright 2008, American Society for Microbiology. All Rights Reserved. Validation
More informationDiagnosis,Therapy and Prophylaxis of Fungal Diseases
mycoses Diagnosis,Therapy and Prophylaxis of Fungal Diseases Original article Treatment and outcomes of invasive fusariosis: review of 65 cases from the PATH Alliance â registry David L. Horn, 1 Alison
More informationESCMID Online Lecture Library. by author
How To Best Use Antifungal Agents Cornelia Lass-Flörl Division of Hygiene and Medical Microbiology Innsbruck Medical University ESCMID SUMMER SCHOOL 2012 Epidemiology Diagnosis Roadmap Antifungal drugs
More informationPosaconazole: A Broad-Spectrum Triazole Antifungal Agent
REVIEWS OF ANTI-INFECTIVE AGENTS Louis D. Saravolatz, Section Editor INVITED ARTICLE Posaconazole: A Broad-Spectrum Triazole Antifungal Agent Vijayalakshmi Nagappan 1 and Stan Deresinski 2,3 1 Division
More informationMycological Profile of Bronchial Wash Specimens in Patients with Lower Respiratory Tract Infections
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 11 (2017) pp. 176-182 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.611.022
More information